Mostly Markets
Subscribe
Stocks/Health Care/Health Care Equipment

Edwards LifesciencesEW

Health Care Equipment · Irvine, California · In the S&P 500
High qualityPricier than peers
$92.01−2.57%After hours: $92.01 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 11.3% over 1 year
Edwards Lifesciences over 1 yearDaily close, $, to 30 Oct 2026
$80$90Nov2026MarMayJulSep$92.01$80$90NovMarJul$92.01
Source: Nasdaq daily closes
Market value$53.03B
Price to earnings54.6x
Forward P/E29.3x
Dividend yield–
Year to date+7.9%
One year+11.3%
Next earningsWed 4 Nov, after the close
SectorHealth Care
52-week range (closes)
$75.87$95.18

Quality and valuation

How Edwards Lifesciences compares with other health care stocks. A description, not a recommendation.

Edwards Lifesciences and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Edwards Lifesciences trades at 29.3 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +14.6% vs +7.8%
  • Keeps more of each sale (gross margin): 77.8% vs 65.3%
  • More profitable (operating margin): 22.3% vs 13.3%
  • Turns more of its sales into cash: 22.0% vs 15.9%
EW trades at 29.3x forward earnings, above the sector medianForward p/e, Health Care Equipment peers
BSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 52.9x earnings, EW is pricier than its average since Jul 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x40xAverage 27.6x2025202652.9x20x40xAverage 27.6x2025202652.9x
Source: Nasdaq prices; SEC filings

Financials

From Edwards Lifesciences's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 13.6% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0.0bn$0.5bn$1.0bn$1.5bnQ3 ’24Q1 ’25Q3 ’25$1.7bnQ2 ’26$0bn$1bnQ3 ’24Q1 ’25Q3 ’25$1.7bnQ2 ’26
Source: SEC filings
Growth slowed to +13.6% last quarterRevenue growth, year on year, %
0%5%10%15%Q3 ’24Q1 ’25Q3 ’2513.6%Q2 ’260%10%Q3 ’24Q1 ’25Q3 ’2513.6%Q2 ’26
Source: SEC filings
Operating margin was 29.5% last quarterOperating income as a share of revenue, %
0%10%20%Q3 ’24Q1 ’25Q3 ’2529.5%Q2 ’260%10%20%Q3 ’24Q1 ’25Q3 ’2529.5%Q2 ’26
Source: SEC filings
Free cash flow was $1.4 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400mQ3 ’24Q1 ’25Q3 ’25$585mQ2 ’26$0m$500mQ3 ’24Q1 ’25Q3 ’25$585mQ2 ’26
Source: SEC filings
Last 12 monthsEWSector median
Revenue growth+14.6%+7.8%
Gross margin77.8%65.3%
Operating margin22.3%13.3%
Free cash flow margin22.0%15.9%
Price to earnings54.6x30.2x

Stories on Edwards Lifesciences

We haven't written about Edwards Lifesciences yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ABTAbbott Laboratories$106.20+1.56%−15.2%$184B
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
IDXXIdexx Laboratories$551.21−4.30%−18.5%$43.42B
GEHCGE HealthCare$76.57+0.20%−6.6%$34.62B